neoplasms

Sarcopenia and Cachexia in Older Patients with Cancer: Pathophysiology, Diagnosis, Impact on Outcomes, and Management Strategies.

Sarcopenia and cachexia are two common and overlapping but distinct muscle wasting syndromes that predict adverse outcomes and undermine quality of life among older adults with cancer. Despite their prognostic value and negative effects on older patients' well-being, sarcopenia and...

🗓️ 2025-10-08
📰 Publication: Drugs & Aging
Read MoreSarcopenia and Cachexia in Older Patients with Cancer: Pathophysiology, Diagnosis, Impact on Outcomes, and Management Strategies.

Adipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia.

Colorectal cancer (CRC) is a leading cause of cancer-related deaths and obesity is a known risk factor for its development and poor prognosis. Adipose tissue (AT) actively contributes to CRC progression and cachexia. Here, we investigated molecular crosstalk between tumor...

🗓️ 2025-10-06
📰 Publication: Cell Death & Disease
Read MoreAdipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia.

Silencing Myostatin Using In Vivo Self-Assembled siRNA Protects Against Cancer- and Dexamethasone-Induced Muscle Atrophy.

Maintaining skeletal muscle mass is crucial for health, as muscle atrophy caused by drugs, cancer, or aging poses serious risks. However, there are few effective pharmacological interventions targeting muscle atrophy, highlighting the need for new therapeutic strategies. In this study,...

🗓️ 2025-10-03
📰 Publication: Advanced Healthcare Materials
Read MoreSilencing Myostatin Using In Vivo Self-Assembled siRNA Protects Against Cancer- and Dexamethasone-Induced Muscle Atrophy.

New models for cancer cachexia and their application to drug discovery.

Cancer cachexia (CC) is a multifactorial syndrome characterized by progressive weight loss, anorexia, and loss of skeletal muscle and fat mass, resulting in reduced quality of life and poor prognosis. Currently, there are no approved pharmacological treatments for CC, highlighting...

🗓️ 2025-10-03
📰 Publication: Expert Opinion On Drug Discovery
Read MoreNew models for cancer cachexia and their application to drug discovery.

Assessing the need for multimodal care in anorexia and cachexia patients with advanced cancer referred to palliative care: a secondary analysis of a multicenter survey in Japan.

There are no methods for assessing the need for multimodal care in cancer cachexia. We examined nine components in evaluating needs among advanced cancer patients. This was a self-administered survey. Participants rated their nutrition impact symptoms (NISs) using a numerical...

🗓️ 2025-09-06
📰 Publication: Supportive Care In Cancer
Read MoreAssessing the need for multimodal care in anorexia and cachexia patients with advanced cancer referred to palliative care: a secondary analysis of a multicenter survey in Japan.

Pre-surgery gut microbial diversity and abundance are associated with post-surgery onset of cachexia in colorectal cancer patients: the ColoCare Study.

Cachexia accounts for about 20% of all cancer-related deaths and it is indicative of poor prognosis and progressive functional impairment. The role of the gut microbiome in the development of cachexia in colorectal cancer (CRC) patients has not been established....

🗓️ 2025-09-04
📰 Publication: Cancer Causes & Control
Read MorePre-surgery gut microbial diversity and abundance are associated with post-surgery onset of cachexia in colorectal cancer patients: the ColoCare Study.

Beyond Body Mass Index: The Impact of Height and Height-Normalised Weight on Overall Survival of Lung Cancer Undergoing Surgery.

Unlike most malignancies, increased adiposity, as expressed by a higher body mass index (BMI), is associated with improved prognosis after lung cancer surgery at the population level. Height, one of the determinants of BMI, is associated with better survival, independent...

🗓️ 2025-08-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreBeyond Body Mass Index: The Impact of Height and Height-Normalised Weight on Overall Survival of Lung Cancer Undergoing Surgery.

Promoting mitochondrial fusion is protective against cancer-induced muscle detriments in males and females.

Skeletal muscle atrophy during cancer-induced cachexia remains a significant challenge in cancer management. Mitochondrial defects precede muscle mass and functional losses in models of cancer cachexia (CC). We hypothesized targeting Opa1-a key regulator of mitochondrial fusion-can attenuate LLC-induced CC outcomes....

🗓️ 2025-08-11
Read MorePromoting mitochondrial fusion is protective against cancer-induced muscle detriments in males and females.

Vagal blockade of the brain-liver axis deters cancer-associated cachexia.

Cancer-associated cachexia (CAC) is a multifactorial and currently incurable syndrome responsible for nearly one-third of cancer-related deaths. It contributes to therapy resistance and increases mortality among affected patients. In this study, we show that cancer-induced systemic inflammation alters vagal tone...

🗓️ 2025-07-29
📰 Publication: Cell
Read MoreVagal blockade of the brain-liver axis deters cancer-associated cachexia.

Exploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis.

AI-driven automated body composition analysis (BCA) may provide quantitative prognostic biomarkers derived from routine staging CTs. This two-centre study evaluates the prognostic value of these volumetric markers for overall survival in lung cancer patients. Lung cancer cohorts from Hospital A...

🗓️ 2025-08-01
📰 Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreExploration of Fully-Automated Body Composition Analysis Using Routine CT-Staging of Lung Cancer Patients for Survival Prognosis.

Cancer therapy and cachexia.

A central challenge in cancer therapy is the effective delivery of anticancer treatments while minimizing adverse effects on patient health. The potential dual impact of therapy is clearly illustrated in cancer-associated cachexia, a multifactorial syndrome characterized by involuntary weight loss,...

🗓️ 2025-08-01
📰 Publication: Journal Of Clinical Investigation
Read MoreCancer therapy and cachexia.

Sarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer.

Patients with sarcopenia and elevated body mass index (BMI) are at high risk of platinum-associated adverse events (AEs). This study examines the association between sarcopenia, BMI, and AEs in patients with non-small cell lung cancer (NSCLC). This retrospective cohort study...

🗓️ 2025-07-30
📰 Publication: Journal Of The National Comprehensive Cancer Network
Read MoreSarcopenia, Elevated Body Mass Index, and Platinum-Associated Adverse Events in Patients With Lung Cancer.

Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Pharmacologic options for managing anorexia in cancer cachexia are limited. This trial aimed to evaluate the efficacy of olanzapine in alleviating anorexia in patients with incurable cancer and cachexia. This double-blind, placebo-controlled, randomized trial included adult patients with incurable cancer...

🗓️ 2025-07-30
📰 Publication: Journal Of The National Comprehensive Cancer Network
Read MoreOlanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!